NCT05435729View on ClinicalTrials.gov

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

December 2, 2022

Conditions
Levodopa-induced DyskinesiaParkinson's Disease
Interventions
DRUG

DSP-9632P 27.5 mg

Single dose of DSP-9632P 27.5 mg

DRUG

DSP-9632P 82.5 mg

Single dose of DSP-9632P 82.5 mg

DRUG

Placebo

Placebo for DSP-9632P

DRUG

DSP-9632P 55.0 mg

Multiple dose of DSP-9632P 55.0 mg

DRUG

Levodopa formulation

Single dose of Levodopa formulation

Trial Locations (1)

Unknown

Nippon Medical School Hospital, Bunkyo

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY